Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 8
2003 8
2004 4
2005 10
2006 9
2007 5
2008 5
2009 5
2010 4
2011 8
2012 6
2013 5
2014 4
2015 4
2016 5
2017 10
2018 7
2019 10
2020 7
2021 7
2022 6
2023 7
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

132 results

Results by year

Filters applied: . Clear all
Page 1
1,5-Disubstituted tetrazoles as PD-1/PD-L1 antagonists.
van der Straat R, Draijer R, Surmiak E, Butera R, Land L, Magiera-Mularz K, Musielak B, Plewka J, Holak TA, Dömling A. van der Straat R, et al. Among authors: holak ta. RSC Med Chem. 2024 Feb 21;15(4):1210-1215. doi: 10.1039/d3md00746d. eCollection 2024 Apr 24. RSC Med Chem. 2024. PMID: 38665826 Free PMC article.
Solubilizer Tag Effect on PD-L1/Inhibitor Binding Properties for m-Terphenyl Derivatives.
Surmiak E, Ząber J, Plewka J, Wojtanowicz G, Kocik-Krol J, Kruc O, Muszak D, Rodríguez I, Musielak B, Viviano M, Castellano S, Skalniak L, Magiera-Mularz K, Holak TA, Kalinowska-Tłuścik J. Surmiak E, et al. Among authors: holak ta. ACS Med Chem Lett. 2023 Dec 14;15(1):36-44. doi: 10.1021/acsmedchemlett.3c00306. eCollection 2024 Jan 11. ACS Med Chem Lett. 2023. PMID: 38229762 Free PMC article.
A combined approach of structure-based virtual screening and NMR to interrupt the PD-1/PD-L1 axis: Biphenyl-benzimidazole containing compounds as novel PD-L1 inhibitors.
Donati G, Viviano M, D'Amore VM, Cipriano A, Diakogiannaki I, Amato J, Tomassi S, Brancaccio D, Russomanno P, Di Leva FS, Arosio D, Seneci P, Taliani S, Magiera-Mularz K, Musielak B, Skalniak L, Holak TA, Castellano S, La Pietra V, Marinelli L. Donati G, et al. Among authors: holak ta. Arch Pharm (Weinheim). 2024 Mar;357(3):e2300583. doi: 10.1002/ardp.202300583. Epub 2023 Dec 18. Arch Pharm (Weinheim). 2024. PMID: 38110703
Discovery of Inhibitory Fragments That Selectively Target Spire2-FMN2 Interaction.
Kitel R, Surmiak E, Borggräfe J, Kalinowska-Tluscik J, Golik P, Czub M, Uzar W, Musielak B, Madej M, Popowicz GM, Dubin G, Holak TA. Kitel R, et al. Among authors: holak ta. J Med Chem. 2023 Dec 14;66(23):15715-15727. doi: 10.1021/acs.jmedchem.3c00877. Epub 2023 Dec 1. J Med Chem. 2023. PMID: 38039505 Free PMC article.
Structural and biological characterization of pAC65, a macrocyclic peptide that blocks PD-L1 with equivalent potency to the FDA-approved antibodies.
Rodriguez I, Kocik-Krol J, Skalniak L, Musielak B, Wisniewska A, Ciesiołkiewicz A, Berlicki Ł, Plewka J, Grudnik P, Stec M, Siedlar M, Holak TA, Magiera-Mularz K. Rodriguez I, et al. Among authors: holak ta. Mol Cancer. 2023 Sep 7;22(1):150. doi: 10.1186/s12943-023-01853-4. Mol Cancer. 2023. PMID: 37679783 Free PMC article.
Design, Synthesis, and Biological Evaluation of 2-Hydroxy-4-phenylthiophene-3-carbonitrile as PD-L1 Antagonist and Its Comparison to Available Small Molecular PD-L1 Inhibitors.
Ważyńska MA, Butera R, Requesens M, Plat A, Zarganes-Tzitzikas T, Neochoritis CG, Plewka J, Skalniak L, Kocik-Krol J, Musielak B, Magiera-Mularz K, Rodriguez I, Blok SN, de Bruyn M, Nijman HW, Elsinga PH, Holak TA, Dömling A. Ważyńska MA, et al. Among authors: holak ta. J Med Chem. 2023 Jul 27;66(14):9577-9591. doi: 10.1021/acs.jmedchem.3c00254. Epub 2023 Jul 14. J Med Chem. 2023. PMID: 37450644 Free PMC article.
132 results